Zombie SPACs and Blood Baths

By John Kahn, Partner, CFGI You may have heard about the massive spike in the popularity of SPACs, but have you heard about Zombie SPACs and Blood Baths? Writing this in Atlanta, Georgia, home of “The Walking Dead” TV show, makes it easier to appreciate that a “Zombie SPAC” is a SPAC without enough life… More

Third Harmonic Bio Closes Upsized Initial Public Offering of Shares of Common Stock Trading on the NASDAQ Global Market

CFGI’s Life Sciences team assisted Third Harmonic Bio (NASDAQ: THRD) with their initial public offering.


Senti Biosciences Completes Merger With Dynamics Special Purpose Corp.

CFGI’s Capital Markets team assisted Senti Biosciences, Incorporated (“Senti Bio”) with the completion of its merger with Dynamics Special Purpose Corporation (“DYNS”) (Nasdaq: DYNS), a special purpose acquisition company.


BCP Raptor Holdco LP Completes Reverse Merger With Altus Midstream Company

CFGI’s Capital Markets team assisted privately-owned BCP Raptor Holdco LP (“BCP”), the parent company of EagleClaw Midstream, with the completion of an all-stock business combination with Altus Midstream Company (Nasdaq: ALTM) (“Altus”), creating a unique, fully-integrated midstream company.


The Future Is Already Here, and CFOs Need to Transform Finance to Survive

Download the Whitepaper

Capital Markets Advisory: 2021 Year in Review

2021 was an exciting year of growth for CFGI, which included a new partnership with CVC Capital Partners, one of the world’s largest private equity firms.


Enjoy Technology Completes Business Combination With Marquee Raine Acquisition Corp.

CFGI’s Capital Markets team assisted Enjoy Technology, Inc.


Securities and Exchange Commission (SEC) Amends Requirements to MD&A

The Securities and Exchange Commission (SEC) recently adopted new amendments as part of an ongoing effort to “modernize and enhance” regulations related to financial disclosures as well as management’s discussion and analysis (MD&A).


atai Life Sciences Launches Initial Public Offering

CFGI’s Capital Markets team supported atai Life Sciences B.